← Leaderboards
Mark E Schurdak
University Of Pittsburgh At Pittsburgh
$7,669,687
Attributed
$11,252,845
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,105,017 · 6
FDA$250,000 · 1
By mechanism
U24$7,865,659 · 2
U2C$5,381,705 · 2
R56$782,279 · 1
U01$250,000 · 1
P30$75,374 · 1
Top collaborators
- Albert H Gough4 shared
- D. Lansing Taylor4 shared
- Lawrence A Vernetti3 shared
- Mark T. Miedel2 shared
- Alejandro Soto-Gutierrez2 shared
- Timothy R Lezon1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joel S Greenberger$22,565,586
- Mark T. Miedel$2,142,086
- Cameron S. Carter$36,474,007
- Khaled A Abdel-Kader$2,565,864
- Jaideep Behari$4,660,334
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsDrug DiscoveryCellsDrug DevelopmentUniversitiesEnsureCollaborationsDrug EfficacyDesignTissue MicroarrayMemberReagentToxic EffectTechnologyProtocols DocumentationEfficacy TestingMetadataLiverEnvironmentIndustryPharmaceutical PreparationsExperimental ModelsPerformancePhysiology
Grant awards (14)
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,540,258
U2C · FY2025 · TR · contact PI
MPS Qualification Section$1,131,489
U2C · FY2025 · TR · contact PI
DDT-IST-000034 Liver acinus microphysiological systems (LAMPS) for determining drug candidate dosing in clinical trials of liver disease.$250,000
U01 · FY2025 · FD · contact PI
Qualification of Patient-Derived Biomimetic Liver MPS as Drug Discovery Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing and Clinical Trial Cohort Selection$1,561,914
U2C · FY2024 · TR · contact PI
MPS Qualification Section$1,148,044
U2C · FY2024 · TR · contact PI
Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource$1,481,809
U24 · FY2022 · TR · contact PI
Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource$1,499,999
U24 · FY2021 · TR · contact PI
University of Pittsburgh Microphysiology Systems Database Center$1,074,147
U24 · FY2019 · TR · contact PI
Chemical Biology Facility$75,374
P30 · FY2019 · CA · contact PI
University of Pittsburgh Microphysiology Systems Database Center$1,084,147
U24 · FY2018 · TR · contact PI
Phenotypic screening and computational modeling for development of combination therapies for Alzheimer's disease$782,279
R56 · FY2018 · AG
University of Pittsburgh Tissue Chip Testing Center$1,052,518
U24 · FY2017 · TR · contact PI
University of Pittsburgh Tissue Chip Testing Center$619,156
U24 · FY2017 · TR · contact PI
University of Pittsburgh Tissue Chip Testing Center$1,053,883
U24 · FY2016 · TR · contact PI